WG
KRTX

Winton Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Winton Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,747
Closed -$317K – 1180
2023
Q1 		$317K Buy
+1,747
New +$334K 0.02% 806
2022
Q3 		– Sell
-3,719
Closed -$470K – 1115
2022
Q2 		$470K Buy
+3,719
New +$427K 0.02% 709

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winton Group's KRTX Position: Q2 2023 in Review

Winton Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 1,747 shares — an estimated $317K sold.

Winton Group first reported a position in KRTX in Q2 2022 and held it in 2 quarters. The position peaked at $470K in Q2 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Winton Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 1,747 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $317K.
  • Winton Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Winton Group's Karuna Therapeutics, Inc. Common Stock position peaked at $470K in Q2 2022.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.